202 related articles for article (PubMed ID: 32675303)
21. In vivo Modeling Implicates APOL1 in Nephropathy: Evidence for Dominant Negative Effects and Epistasis under Anemic Stress.
Anderson BR; Howell DN; Soldano K; Garrett ME; Katsanis N; Telen MJ; Davis EE; Ashley-Koch AE
PLoS Genet; 2015 Jul; 11(7):e1005349. PubMed ID: 26147622
[TBL] [Abstract][Full Text] [Related]
22. ApoL1 renal risk variants induce aberrant THP-1 monocyte differentiation and increase eicosanoid production via enhanced expression of cyclooxygenase-2.
Lee H; Roshanravan H; Wang Y; Okamoto K; Ryu J; Shrivastav S; Qu P; Kopp JB
Am J Physiol Renal Physiol; 2018 Jul; 315(1):F140-F150. PubMed ID: 29357411
[TBL] [Abstract][Full Text] [Related]
23. APOL1 renal risk variants promote cholesterol accumulation in tissues and cultured macrophages from APOL1 transgenic mice.
Ryu JH; Ge M; Merscher S; Rosenberg AZ; Desante M; Roshanravan H; Okamoto K; Shin MK; Hoek M; Fornoni A; Kopp JB
PLoS One; 2019; 14(4):e0211559. PubMed ID: 30998685
[TBL] [Abstract][Full Text] [Related]
24. APOL1 Nephrotoxicity: What Does Ion Transport Have to Do With It?
Olabisi OA; Heneghan JF
Semin Nephrol; 2017 Nov; 37(6):546-551. PubMed ID: 29110762
[TBL] [Abstract][Full Text] [Related]
25. Transcription and translation of
Ejaz S
Biosci Rep; 2017 Oct; 37(5):. PubMed ID: 28842513
[TBL] [Abstract][Full Text] [Related]
26. Inaxaplin for Proteinuric Kidney Disease in Persons with Two
Egbuna O; Zimmerman B; Manos G; Fortier A; Chirieac MC; Dakin LA; Friedman DJ; Bramham K; Campbell K; Knebelmann B; Barisoni L; Falk RJ; Gipson DS; Lipkowitz MS; Ojo A; Bunnage ME; Pollak MR; Altshuler D; Chertow GM;
N Engl J Med; 2023 Mar; 388(11):969-979. PubMed ID: 36920755
[TBL] [Abstract][Full Text] [Related]
27.
Ma L; Palmer ND; Choi YA; Murea M; Snipes JA; Parks JS; Langefeld CD; Freedman BI
Kidney360; 2020 Dec; 1(12):1353-1362. PubMed ID: 35372896
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1-second gene interactions.
Langefeld CD; Comeau ME; Ng MCY; Guan M; Dimitrov L; Mudgal P; Spainhour MH; Julian BA; Edberg JC; Croker JA; Divers J; Hicks PJ; Bowden DW; Chan GC; Ma L; Palmer ND; Kimberly RP; Freedman BI
Kidney Int; 2018 Sep; 94(3):599-607. PubMed ID: 29885931
[TBL] [Abstract][Full Text] [Related]
29. Novel Human Podocyte Cell Model Carrying G2/G2 APOL1 High-Risk Genotype.
Ekulu PM; Adebayo OC; Decuypere JP; Bellucci L; Elmonem MA; Nkoy AB; Mekahli D; Bussolati B; van den Heuvel LP; Arcolino FO; Levtchenko EN
Cells; 2021 Jul; 10(8):. PubMed ID: 34440683
[TBL] [Abstract][Full Text] [Related]
30. Ten years in: APOL1 reaches beyond the kidney.
Waitzman JS; Lin J
Curr Opin Nephrol Hypertens; 2019 Jul; 28(4):375-382. PubMed ID: 31082862
[TBL] [Abstract][Full Text] [Related]
31. Apolipoprotein L1 High-Risk Genotypes and Albuminuria in Sub-Saharan African Populations.
Brandenburg JT; Govender MA; Winkler CA; Boua PR; Agongo G; Fabian J; Ramsay M
Clin J Am Soc Nephrol; 2022 Jun; 17(6):798-808. PubMed ID: 35577564
[TBL] [Abstract][Full Text] [Related]
32. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.
Lan X; Jhaveri A; Cheng K; Wen H; Saleem MA; Mathieson PW; Mikulak J; Aviram S; Malhotra A; Skorecki K; Singhal PC
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F326-36. PubMed ID: 24899058
[TBL] [Abstract][Full Text] [Related]
33. APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease.
Datta S; Antonio BM; Zahler NH; Theile JW; Krafte D; Zhang H; Rosenberg PB; Chaves AB; Muoio DM; Zhang G; Silas D; Li G; Soldano K; Nystrom S; Ferreira D; Miller SE; Bain JR; Muehlbauer MJ; Ilkayeva O; Becker TC; Hohmeier HE; Newgard CB; Olabisi OA
J Clin Invest; 2024 Jan; 134(5):. PubMed ID: 38227370
[TBL] [Abstract][Full Text] [Related]
34.
Ma L; Chou JW; Snipes JA; Bharadwaj MS; Craddock AL; Cheng D; Weckerle A; Petrovic S; Hicks PJ; Hemal AK; Hawkins GA; Miller LD; Molina AJ; Langefeld CD; Murea M; Parks JS; Freedman BI
J Am Soc Nephrol; 2017 Apr; 28(4):1093-1105. PubMed ID: 27821631
[No Abstract] [Full Text] [Related]
35. APOL1 Genetic Variants Are Associated with Serum-Oxidized Low-Density Lipoprotein Levels and Subclinical Atherosclerosis in South African CKD Patients.
Hassan MO; Duarte R; Dickens C; Dix-Peek T; Naidoo S; Vachiat A; Grinter S; Manga P; Naicker S
Nephron; 2020; 144(7):331-340. PubMed ID: 32526749
[TBL] [Abstract][Full Text] [Related]
36. Gene of the month:
Raghubeer S; Pillay TS; Matsha TE
J Clin Pathol; 2020 Aug; 73(8):441-443. PubMed ID: 32404472
[TBL] [Abstract][Full Text] [Related]
37. APOL1-G1 in Nephrocytes Induces Hypertrophy and Accelerates Cell Death.
Fu Y; Zhu JY; Richman A; Zhang Y; Xie X; Das JR; Li J; Ray PE; Han Z
J Am Soc Nephrol; 2017 Apr; 28(4):1106-1116. PubMed ID: 27864430
[TBL] [Abstract][Full Text] [Related]
38. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.
Beckerman P; Bi-Karchin J; Park AS; Qiu C; Dummer PD; Soomro I; Boustany-Kari CM; Pullen SS; Miner JH; Hu CA; Rohacs T; Inoue K; Ishibe S; Saleem MA; Palmer MB; Cuervo AM; Kopp JB; Susztak K
Nat Med; 2017 Apr; 23(4):429-438. PubMed ID: 28218918
[TBL] [Abstract][Full Text] [Related]
39.
Zhang JY; Wang M; Tian L; Genovese G; Yan P; Wilson JG; Thadhani R; Mottl AK; Appel GB; Bick AG; Sampson MG; Alper SL; Friedman DJ; Pollak MR
Proc Natl Acad Sci U S A; 2018 Mar; 115(13):3446-3451. PubMed ID: 29531077
[TBL] [Abstract][Full Text] [Related]
40.
Ma L; Ainsworth HC; Snipes JA; Murea M; Choi YA; Langefeld CD; Parks JS; Bharadwaj MS; Chou JW; Hemal AK; Petrovic S; Craddock AL; Cheng D; Hawkins GA; Miller LD; Hicks PJ; Saleem MA; Divers J; Molina AJA; Freedman BI
Kidney Int Rep; 2020 Jun; 5(6):891-904. PubMed ID: 32518871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
